Moderna(US:MRNA) 智通财经网·2025-10-08 15:35Core Viewpoint - Moderna's stock price increased by over 6.7% to $29.17 following the CDC's announcement regarding changes in vaccination guidelines, particularly for COVID-19 vaccines [1] Group 1: CDC Announcement - The CDC has introduced a new immunization strategy that incorporates COVID-19 vaccines into an "individualized decision-making" model [1] - The new guidelines suggest that children should receive the varicella (chickenpox) vaccine separately rather than in combination with measles, mumps, and rubella vaccines [1] - Jim O'Neill, the acting director of the CDC, emphasized that the new policy restores informed consent to medical practice, allowing for better discussions between doctors and patients regarding vaccine risks and benefits [1] Group 2: Target Population - The updated recommendations indicate that the benefits of COVID-19 vaccination are greater for high-risk individuals under 65, while low-risk individuals can decide with their doctors whether to get vaccinated [1]